Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Xueli Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8306-0639; OpenAlex author ID A5100777374, A5130226300. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
55
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 5 papers · 2026: 3 papers

Papers 18

  1. A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neuron.2026.03.039↗
  2. A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-026-03864-z↗
  3. Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis. Co-author DOI 10.1038/s41419-026-08613-4↗
  4. Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adeno… Last author DOI 10.1002/cac2.12637↗
  5. Vitamin K-dependent gamma-carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosin… Co-author DOI 10.1002/ctm2.70191↗
  6. ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling. Last author DOI 10.1016/j.tranon.2024.102261↗
  7. Histone serotonylation promotes pancreatic cancer development via lipid metabolism remodeling. Co-author DOI 10.1038/s41467-025-61197-z↗
  8. B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. Last author DOI 10.1136/jitc-2024-010908↗
  9. Retraction Note: Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10142-024-01383-2↗
  10. Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10142-023-01020-4↗
  11. METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity. Last author DOI 10.1007/s13402-023-00829-2↗
  12. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-02159-9↗
  13. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Co-author DOI 10.1038/s41389-021-00311-4↗
  14. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-020-20447-y↗
  15. Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC. Co-author DOI 10.1155/2021/6694392↗
  16. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Co-author DOI 10.1136/gutjnl-2018-317479↗
  17. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.21037/cco.2019.03.02↗
  18. MicroRNA-224 Promotes Pancreatic Cancer Cell Proliferation and Migration by Targeting the TXNIP-Mediated HIF1α Pathway. Last author DOI 10.1159/000492309↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhigang Zhang · 13 shared papers, 2019–2026 · strength 2.17
  2. Shu‐Heng Jiang · 12 shared papers, 2019–2026 · strength 1.95
  3. Li-Peng Hu · 10 shared papers, 2019–2026 · strength 1.43
  4. Xiaomei Yang · 8 shared papers, 2019–2026 · strength 1.37
  5. Linli Yao · 8 shared papers, 2021–2026 · strength 1.26
  6. Aziguli Tulamaiti · 4 shared papers, 2025–2026 · strength 0.93
  7. Hui Nie · 6 shared papers, 2019–2025 · strength 0.83
  8. Dong‐Xue Li · 3 shared papers, 2025 · strength 0.62
  9. Dejun Liu · 3 shared papers, 2022–2026 · strength 0.53
  10. Yan-Zhi Gai · 3 shared papers, 2022–2024 · strength 0.46
  11. Qing Ye · 2 shared papers, 2025–2026 · strength 0.44
  12. Xia-Qing Li · 2 shared papers, 2025 · strength 0.43
  13. Dongxue Li · 2 shared papers, 2022–2026 · strength 0.41
  14. Hong‐Fei Yao · 2 shared papers, 2025–2026 · strength 0.41
  15. Hui Li · 2 shared papers, 2024–2026 · strength 0.38
  16. Shan Zhang · 2 shared papers, 2023–2025 · strength 0.37
  17. Yingna Liao · 2 shared papers, 2023–2024 · strength 0.34
  18. Yan‐Miao Huo · 2 shared papers, 2021–2026 · strength 0.33
  19. Kaixia Zhou · 3 shared papers, 2021 · strength 0.32
  20. Qing Li · 3 shared papers, 2021–2022 · strength 0.32
  21. Xin Xing · 2 shared papers, 2021–2025 · strength 0.32
  22. Xu Wang · 3 shared papers, 2019–2021 · strength 0.30
  23. Yunzhen Qian · 1 shared paper, 2026 · strength 0.29
  24. Qi An · 1 shared paper, 2026 · strength 0.29
  25. Yongwei Sun · 3 shared papers, 2019–2022 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.